Total Payments
$317,876
2024 Payments
$30,105
Companies
39
Transactions
289
Medicare Patients
3,392
Medicare Billing
$580,002
Payment Breakdown by Category
Consulting$224,526 (70.6%)
Other$32,330 (10.2%)
Education$25,760 (8.1%)
Travel$20,394 (6.4%)
Food & Beverage$12,539 (3.9%)
Research$2,327 (0.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $224,526 | 59 | 70.6% |
| Honoraria | $28,060 | 9 | 8.8% |
| Education | $25,760 | 16 | 8.1% |
| Travel and Lodging | $20,394 | 47 | 6.4% |
| Food and Beverage | $12,539 | 155 | 3.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,270 | 2 | 1.3% |
| Unspecified | $2,327 | 1 | 0.7% |
Payments by Type
General
$315,549
288 transactions
Research
$2,327
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Photocure Inc | $132,879 | 79 | $0 (2024) |
| Ferring Pharmaceuticals Inc. | $38,930 | 34 | $0 (2024) |
| Janssen Research & Development, LLC | $37,219 | 22 | $0 (2024) |
| Olympus Corporation of the Americas | $27,530 | 43 | $0 (2020) |
| Ferring Pharmaceuticals AS | $11,943 | 5 | $0 (2024) |
| UroGen Pharma, Inc. | $11,059 | 7 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $10,625 | 11 | $0 (2024) |
| Janssen Global Services, LLC | $10,223 | 26 | $0 (2023) |
| PFIZER INC. | $10,067 | 7 | $0 (2024) |
| Guard Medical Inc. | $4,250 | 2 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $30,105 | 29 | Janssen Research & Development, LLC ($12,594) |
| 2023 | $65,865 | 58 | Photocure Inc ($30,506) |
| 2022 | $11,434 | 20 | Astellas Pharma Global Development ($3,512) |
| 2021 | $35,944 | 19 | Photocure Inc ($17,788) |
| 2020 | $50,299 | 29 | Janssen Research & Development, LLC ($12,210) |
| 2019 | $48,603 | 56 | Ferring Pharmaceuticals Inc. ($32,409) |
| 2018 | $50,957 | 47 | Photocure Inc ($36,154) |
| 2017 | $24,671 | 31 | Photocure Inc ($21,581) |
All Payment Transactions
289 individual payment records from CMS Open Payments — Page 1 of 12
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Ferring Pharmaceuticals Inc. | ADSTILADRIN (Biological) | Consulting Fee | Cash or cash equivalent | $935.00 | General |
| Category: ONCOLOGY | ||||||
| 12/05/2024 | Fennec Pharmaceuticals, Inc. | Pedmark (Drug) | Food and Beverage | In-kind items and services | $50.81 | General |
| Category: Cisplatin-induced Ototoxicity | ||||||
| 11/19/2024 | Photocure Inc | CYSVIEW (Drug) | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| Category: ONCOLOGY | ||||||
| 11/09/2024 | Ferring Pharmaceuticals AS | ADSTILADRIN (Biological) | Travel and Lodging | In-kind items and services | $670.45 | General |
| Category: ONCOLOGY | ||||||
| 11/09/2024 | Ferring Pharmaceuticals AS | ADSTILADRIN (Biological) | Travel and Lodging | In-kind items and services | $296.46 | General |
| Category: ONCOLOGY | ||||||
| 11/09/2024 | Ferring Pharmaceuticals AS | ADSTILADRIN (Biological) | Food and Beverage | In-kind items and services | $126.00 | General |
| Category: ONCOLOGY | ||||||
| 10/24/2024 | Medtronic, Inc. | LIGASURE (Device) | Food and Beverage | In-kind items and services | $33.20 | General |
| Category: Vessel Sealing | ||||||
| 10/23/2024 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $7,362.50 | General |
| 09/30/2024 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $2,325.00 | General |
| 09/20/2024 | Guard Medical Inc. | NPSEAL LARGE (Device) | Consulting Fee | Cash or cash equivalent | $1,700.00 | General |
| Category: NEGATIVE PRESSURE WOUND THERAPY | ||||||
| 07/23/2024 | Ferring Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $90.54 | General |
| 07/09/2024 | Photocure Inc | CYSVIEW (Drug) | Food and Beverage | In-kind items and services | $141.62 | General |
| Category: ONCOLOGY | ||||||
| 07/02/2024 | Medtronic, Inc. | LIGASURE (Device) | Food and Beverage | In-kind items and services | $26.29 | General |
| Category: Vessel Sealing | ||||||
| 06/19/2024 | PFIZER INC. | PADCEV (Biological) | Honoraria | Cash or cash equivalent | $5,560.00 | General |
| Category: Oncology | ||||||
| 05/31/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $71.24 | General |
| Category: Oncology | ||||||
| 05/31/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $39.11 | General |
| Category: Oncology | ||||||
| 05/30/2024 | PFIZER INC. | PADCEV (Biological) | Travel and Lodging | In-kind items and services | $523.95 | General |
| Category: Oncology | ||||||
| 05/30/2024 | PFIZER INC. | PADCEV (Biological) | Travel and Lodging | In-kind items and services | $370.98 | General |
| Category: Oncology | ||||||
| 05/24/2024 | Medtronic, Inc. | RAPIDVAC (Device) | Food and Beverage | In-kind items and services | $123.11 | General |
| Category: Smoke Evacuation Systems | ||||||
| 05/22/2024 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $1,743.75 | General |
| 05/05/2024 | Ferring Pharmaceuticals Inc. | ADSTILADRIN (Biological) | Food and Beverage | In-kind items and services | $19.96 | General |
| Category: ONCOLOGY | ||||||
| 05/05/2024 | Ferring Pharmaceuticals Inc. | ADSTILADRIN (Biological) | Food and Beverage | In-kind items and services | $17.43 | General |
| Category: ONCOLOGY | ||||||
| 05/03/2024 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $1,162.50 | General |
| 05/01/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $2,400.00 | General |
| 02/08/2024 | Innovation Technologies Inc | IRRISEPT (Device) | Food and Beverage | In-kind items and services | $81.07 | General |
| Category: JET LAVAGE DEVICE WITH CHG | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE III, OPEN-LABEL, MULTICENTER,RANDOMIZED STUDY OF ATEZOLIZUMABANTI-PD-L1 ANTIBODY VERSUS OBSERVATIONAS ADJUVANT THERAPY IN PATIENTS WITHHIGH-RISK MUSCLE-INVASIVE UROTHELIAL CARCINOMA AFTER SURGICAL RESECTION | F. Hoffmann-La Roche AG | $2,327 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 890 | 1,171 | $772,230 | $137,878 |
| 2022 | 15 | 861 | 1,099 | $830,115 | $144,331 |
| 2021 | 19 | 915 | 1,128 | $1.0M | $186,024 |
| 2020 | 13 | 726 | 924 | $635,660 | $111,769 |
Total Patients
3,392
Total Services
4,322
Medicare Billing
$580,002
Procedure Codes
75
All Medicare Procedures & Services
75 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 51596 | Removal of bladder and lymph nodes on both sides of pelvis with transplantation of ureters to small and/or large bowel with creation of urinary opening | Facility | 2023 | 15 | 15 | $147,000 | $29,559 | 20.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 181 | 265 | $106,000 | $21,328 | 20.1% |
| 52000 | Diagnostic exam of bladder and urethra using an endoscope | Facility | 2023 | 166 | 265 | $106,000 | $17,256 | 16.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 189 | 231 | $63,525 | $11,970 | 18.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 57 | 76 | $40,660 | $8,916 | 21.9% |
| 52235 | Destruction and/or removal of growth of bladder and urethra using an endoscope, 2.0-5.0 cm | Facility | 2023 | 29 | 35 | $38,500 | $7,958 | 20.7% |
| 52240 | Destruction and/or removal of large growth of bladder using an endoscope | Facility | 2023 | 18 | 25 | $48,750 | $7,684 | 15.8% |
| 55845 | Removal of prostate gland and surrounding lymph nodes on both sides of pelvis through abdominal incision | Facility | 2023 | 12 | 12 | $93,000 | $6,856 | 7.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 44 | 44 | $33,000 | $6,465 | 19.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 44 | 44 | $26,400 | $4,871 | 18.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 36 | 44 | $17,600 | $3,885 | 22.1% |
| 52224 | Destruction of growth of bladder and urethra using an endoscope, less than 0.5 cm | Facility | 2023 | 17 | 22 | $15,400 | $3,622 | 23.5% |
| 52234 | Destruction and/or removal of growth of bladder and urethra using an endoscope, 0.5-2.0 cm | Facility | 2023 | 15 | 17 | $13,600 | $3,274 | 24.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 42 | 49 | $13,475 | $2,697 | 20.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 11 | 11 | $6,600 | $1,086 | 16.5% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Facility | 2023 | 14 | 16 | $2,720 | $451.50 | 16.6% |
| 51596 | Removal of bladder and lymph nodes on both sides of pelvis with transplantation of ureters to small and/or large bowel with creation of urinary opening | Facility | 2022 | 19 | 19 | $186,200 | $38,391 | 20.6% |
| 52000 | Diagnostic exam of bladder and urethra using an endoscope | Facility | 2022 | 155 | 249 | $99,600 | $16,677 | 16.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 243 | 302 | $83,050 | $16,583 | 20.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 121 | 170 | $68,000 | $13,979 | 20.6% |
| 55845 | Removal of prostate gland and surrounding lymph nodes on both sides of pelvis through abdominal incision | Facility | 2022 | 16 | 16 | $124,000 | $9,938 | 8.0% |
| 52240 | Destruction and/or removal of large growth of bladder using an endoscope | Facility | 2022 | 17 | 22 | $42,900 | $7,020 | 16.4% |
| 52235 | Destruction and/or removal of growth of bladder and urethra using an endoscope, 2.0-5.0 cm | Facility | 2022 | 24 | 28 | $30,800 | $6,441 | 20.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 41 | 47 | $25,145 | $5,895 | 23.4% |
| 38564 | Removal of lymph nodes behind abdominal cavity | Facility | 2022 | 17 | 17 | $54,570 | $5,231 | 9.6% |
About Dr. Siamak Daneshmand, M.D
Dr. Siamak Daneshmand, M.D is a Urology healthcare provider based in Los Angeles, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/26/2006. The National Provider Identifier (NPI) number assigned to this provider is 1174546568.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Siamak Daneshmand, M.D has received a total of $317,876 in payments from pharmaceutical and medical device companies, with $30,105 received in 2024. These payments were reported across 289 transactions from 39 companies. The most common payment nature is "Consulting Fee" ($224,526).
As a Medicare-enrolled provider, Daneshmand has provided services to 3,392 Medicare beneficiaries, totaling 4,322 services with total Medicare billing of $580,002. Data is available for 4 years (2020–2023), covering 75 distinct procedure/service records.
Ad
Practice Information
- Specialty Urology
- Location Los Angeles, CA
- Active Since 07/26/2006
- Last Updated 11/27/2023
- Taxonomy Code 208800000X
- Entity Type Individual
- NPI Number 1174546568
Products in Payments
- Cysview (Drug) $97,852
- CYSVIEW (Drug) $35,027
- Olympus Cystoscopes (Device) $15,152
- ADSTILADRIN (Drug) $11,327
- Olympus Laser Devices (Device) $11,237
- PADCEV (Biological) $9,459
- JELMYTO (Drug) $6,824
- NPSEAL LARGE (Device) $4,250
- OPDIVO (Biological) $4,224
- TECENTRIQ (Biological) $3,737
- Padcev (Drug) $3,512
- BALVERSA (Drug) $2,145
- ADSTILADRIN (Biological) $2,065
- Olympus Cysto-Resection (Device) $1,080
- DARZALEX (Drug) $266.66
- Surgical Care - Floseal (Biological) $245.00
- PENILE RECONSTRUCTION (Device) $203.38
- Pedmark (Drug) $187.47
- Urolift - UL400 (Device) $153.42
- BOTOX (Biological) $152.66
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Urology Doctors in Los Angeles
Mihir Desai, M.d, M.D
Urology — Payments: $1.6M
Urology $1.6M
Arie Belldegrun, Md, MD
Urology — Payments: $1.3M
Urology $1.3M
Dr. William Aronson, Md, MD
Urology — Payments: $753,306
Urology $753,306
Dr. Stuart Holden
Urology — Payments: $668,127
Urology $668,127
Dr. Jeffrey Loh-Doyle, M.d, M.D
Urology — Payments: $295,721
Urology $295,721
Amir Lebastchi, Md, MD
Urology — Payments: $286,921
Urology $286,921